U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27N3O2
Molecular Weight 377.4794
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GSK-239512

SMILES

O=C1CCCN1C2=CN=C(OC3=CC=C4CCN(CCC4=C3)C5CCC5)C=C2

InChI

InChIKey=YFRBKEVUUCQYOW-UHFFFAOYSA-N
InChI=1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2

HIDE SMILES / InChI

Molecular Formula C23H27N3O2
Molecular Weight 377.4794
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

GlaxoSmithKline (GSK) was developing GSK-239512 as a histamine H3 receptor antagonist/inverse agonist as a monotherapy treatment for subjects with mild-to-moderate probable Alzheimer's disease (AD), multiple sclerosis and Schizophrenia. However, in March 2017, GSK globally discontinued the study of GSK-239512 at phase II.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

In this 16-week, double-blind, randomized, parallel group study, 196 currently untreated subjects with mild-tomoderate AD (Mini Mental State Examination [MMSE] 16-24) received GSK239512 (n=97); or placebo (n=99) administered orally each morning.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:43:02 GMT 2023
Edited
by admin
on Fri Dec 15 17:43:02 GMT 2023
Record UNII
4I7U5C459M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GSK-239512
Common Name English
GSK-239512A
Code English
2-PYRROLIDINONE, 1-(6-((3-CYCLOBUTYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPIN-7-YL)OXY)-3-PYRIDINYL)-
Systematic Name English
GSK239512
Code English
Code System Code Type Description
SMS_ID
100000178152
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
ChEMBL
CHEMBL3092650
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
CAS
720691-69-0
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
GSK-239512
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY This is a randomized, parallel group, placebo-controlled study designed to assess whether GSK239512 can enhance lesion remyelination in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
DRUG BANK
DB15120
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
PUBCHEM
9976892
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
FDA UNII
4I7U5C459M
Created by admin on Fri Dec 15 17:43:02 GMT 2023 , Edited by admin on Fri Dec 15 17:43:02 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Identifies correct structure of GSK-239512.
ACTIVE MOIETY
Class: Anti-dementia, Antipsychotic; Mechanism of Action: Histamine H3 receptor antagonist; Highest Development Phases: Phase II for Multiple sclerosis, No development reported for Alzheimer's disease, Discontinued for Schizophrenia; Most Recent Events: 29 Jun 2015 No recent reports on development identified - Phase-II for Alzheimer's disease in Russia, South Korea, Chile, European Union (PO), 29 Jun 2015 No recent reports on development identified - Phase-I for Alzheimer's disease in Australia (PO), 29 Jun 2015 Discontinued - Phase-II for Schizophrenia in USA (PO)
ACTIVE MOIETY
METHODS: The study was conducted in two parts. Part A was a single-blind, placebo run-in, flexible dose titration over 9 days in two cohorts, each consisting of two patients. Part B was a double-blind, randomised, placebo controlled, parallel group, which investigated 3 flexible dose titration regimens over 4 weeks in 3 cohorts, each consisting of eight patients. RESULTS: Overall, the 5/10/20/40 .MU.g and 10/20/40/80 .MU.g regimens were well-tolerated. The regimen of 10/40/80/150 .MU.g showed the poorest tolerability likely due to the higher starting dose. There were no clinically significant abnormalities in haematology, clinical chemistry, urinalysis parameters and cardiovascular parameters. GSK239512 had positive effects on tasks of attention and memory with effect sizes between 0.56 and 1.37.
ACTIVE MOIETY